Attenuation of Doxorubicin-induced Hepato- and Nephrotoxicity by Proanthocyanidins from Myrica nagi Bark in Wistar Rats

Authors

  • Patil A. Rupali
  • Kasar Mayur S.
  • Pingale Prashant L.

DOI:

https://doi.org/10.37591/rrjot.v10i3.2399

Abstract

Due to dose-related toxic effects, doxorubicin, a very potent and often used anti-cancer medication, is largely limited. The current research investigated the protective impact of Myrica nagi bark (PMN)-isolated proanthocyanidins on hepato-induced doxorubicin and nephrotoxicity in Wistar rats. The animals were subdivided into six classes of five rats each. Group I got PMN (200 mg/kg, p.o.) for 21 days, Group II received Doxorubicin (DXR) (60 mg/kg, i.p.) once, 48 h before sacrifice, Group III received PMN (200 mg/kg, p.o.) for 21 days, Group IV, V, and VI received PMN (200 and 400 mg/kg, p.o.) and Limarin (25 mg/kg, p.o.) for 21 days and DXR (60 mg/kg, i.p.) once, 48 h before sacrifice, respectively. Animals were slaughtered after 21 days and blood samples were obtained for liver and kidney biomarker detection. For in-vivo antioxidant experiments, the upper liver lobe and the right kidney were dissected. There is a substantial decrease in levels of liver and kidney biomarkers in the pre-treatment of PMN in the doxorubicin-treated population. PMN substantially reversed DXR's effects on superoxide dismutase (SOD), catalase (CAT), GSH, and lipid peroxidation levels (LPO). In conclusion, data indicate that chronic administration of Myrica nagi improved DXR may have induced hepatotoxicity and nephrotoxicity via its antioxidant action.

 

Keywords: Doxorubicin, hepatotoxicity, Myrica nagi, nephrotoxicity, proanthocyanidins

 

Cite this Article

Patil Rupali A., Kasar Mayur S., Pingale Prashant L. Attenuation of Doxorubicin-induced Hepato- and Nephrotoxicity by Proanthocyanidins from Myrica nagi Bark in Wistar Rats. Research & Reviews: A Journal of Toxicology. 2020; 10(3): 19–28p.

Downloads

Published

2021-01-11

Issue

Vol. 10 No. 3 (2020)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.